Retatrutide

Description

Retatrutide

Retatrutide, also known by the research code LY3437943, is a synthetic peptide currently being investigated in metabolic and incretin-receptor research. It belongs to the same broad research class as compounds such as semaglutide and tirzepatide, but is distinguished by its activity across three different receptor systems.

Retatrutide is described as a triple receptor agonist, with activity at the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This three-receptor profile has made Retatrutide an important research compound for studying how multiple metabolic signalling pathways may interact.

GLP-1 and GIP receptors are involved in metabolic and glucose-related signalling, while the glucagon receptor participates in pathways associated with glucose regulation and energy metabolism. Researchers study Retatrutide to better understand how simultaneously targeting these three receptors differs from compounds that interact with only one or two of these pathways.

A major area of Retatrutide research involves metabolism, glucose regulation, energy balance, body-weight regulation, and appetite-related signalling. Laboratory and animal studies have examined receptor activity and metabolic responses, while controlled human clinical trials have investigated the compound’s effects on body weight and metabolic measures. These clinical studies have contributed to significant scientific interest in triple-receptor agonists and their potential differences from earlier incretin-based compounds.

Structurally, Retatrutide is a 39-amino-acid peptide containing a lipid side chain attached through a linker. Lipidation is used in peptide research to influence properties such as stability and duration of activity. Researchers have studied this structural design alongside other incretin-receptor peptides to better understand the relationship between peptide structure, receptor activity, and pharmacokinetic behaviour.

Research involving Retatrutide continues to examine its three-receptor mechanism and its relationship with metabolic signalling. Although human clinical research exists, Retatrutide remains an investigational compound and is not an approved therapeutic product in Canada. Research findings should not be interpreted as instructions for use or as establishing the safety or suitability of independently sourced research material for human use.

Quantum Labs Canada supplies Retatrutide as a lyophilized (freeze-dried) powder intended exclusively for controlled laboratory and research applications.

Each batch is independently tested for purity and consistency.

Purity: >99% (lab-verified)
Form: Lyophilized powder
Storage: Store in a cool, dry environment.
Use: FOR RESEARCH AND LAB USE ONLY. Not intended for human or therapeutic use. This compound has not been authorized by Health Canada for therapeutic, clinical, or human use.